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Survival from childhood leukaemia has increased, but the proportion of children cured is unknown. The proportion ‘cured’ is defined
as the proportion of survivors for whom, as a group, there is no longer excess mortality compared to the general population. Average
time to cure is defined as the time since diagnosis at which the excess mortality rate has declined to or below a predetermined small
value. Data on children diagnosed with leukaemia during 1971–2000 in Great Britain were used to estimate trends in survival, the
proportion cured and the average time to cure. Five-year survival for all types of leukaemia combined rose from 33 to 79% by 2000.
The percentage cured rose from 25 to 68% by 1995; it is predicted to increase to 73% for those diagnosed more recently. Average
time to cure increased from 12 years (95% confidence interval (CI): 11–14) to 19 years (95% CI: 14–26) for lymphoid leukaemia
(average annual increase of 0.3 years; Po0.001), but remained at about 5 years for acute nonlymphoblastic leukaemia. The
proportion of children cured of leukaemia has risen dramatically, but the period of excess mortality associated with lymphoid
leukaemia has also increased, possibly because of late relapse, secondary malignancy and toxicity from treatment.
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Leukaemia accounts for approximately one-third of all childhood
malignancies in Great Britain (Swerdlow et al, 2001). Over 400 cases
of childhood leukaemia are diagnosed every year, of which lymphoid
leukaemia represents 80% and the remainder are mostly acute
nonlymphoblastic leukaemia (ANLL). Survival from childhood
leukaemia at 5 years after diagnosis has risen dramatically, from
less than 5% in the early 1960s (Thames Cancer Registry, 1994) to
79% for children diagnosed during 1996–2000 (Stiller et al, 2007).
The increase in survival is attributed to the use of intensive
chemotherapy, combined with other modalities of treatment, and
to improved supportive care (Eden et al, 2000; Gibson et al, 2005).
The number of childhood leukaemia survivors who are alive more
than 10 years after diagnosis has increased as a result, and there
are currently over 5500 long-term survivors in Great Britain.
However, intensive therapies for childhood leukaemia have long-
term adverse effects, including continuing excess mortality beyond
10 years after diagnosis (Hawkins, 1989). Therefore, the propor-
tion of children who are actually ‘cured’, that is, who have a
normal life expectancy after a diagnosis of leukaemia, is not
known.
MATERIALS AND METHODS
Data for children who were diagnosed with leukaemia in Great
Britain during 1971–2000 and followed up until the end of 2004
were obtained from the National Registry of Childhood Tumours
(NRCT), which is managed by the Childhood Cancer Research
Group (CCRG).
The NRCT includes virtually all children resident in Great
Britain who are diagnosed with a malignant neoplasm under the
age of 15 years. The methods of ascertainment to obtain
registrations of children from a variety of population-based
sources by CCRG are described elsewhere (Stiller et al, 2007).
The Childhood Cancer Research Group has received information
from its various sources on an estimated 99% of all cases of
childhood leukaemia diagnosed since 1969.
Childhood cancer patients are routinely flagged at the National
Health Service Central Registers (NHSCR) for England and Wales
and for Scotland approximately 5 years after diagnosis. The
Childhood Cancer Research Group is then notified of any
subsequent cancer registrations, or of the death or emigration of
any of these patients. Information on the vital status of all children
treated by the Children’s Cancer and Leukaemia Group who are
not yet flagged at NHSCR is also received annually by CCRG.
Flagged patients for whom no death or emigration details had been
recorded were assumed to be alive on 31 December 2004.
Leukaemia was classified according to the International Classifica-
tion of Childhood Cancer (Krama´rova´ et al, 1996).
A suite of programmes was used to assess data quality, by
filtering each record through a standard series of checks (Coleman
et al, 1999). Records were considered to be ineligible if they were
incomplete, if they had ineligible morphology codes or were
duplicates. Records were checked for impossible sequences of
dates of birth, diagnosis and follow-up or death, and for zero
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survival. Patients with zero survival were defined as those who
were diagnosed and died on the same day, whose leukaemia was
only detected at postmortem, or who were notified only from a
death certificate (DCO), the last group because date of diagnosis is
unknown.
The population-based data obtained from the NRCT were of
very high quality. Less than 3% of children registered with
leukaemia were lost to follow-up by the end of 2004. No duplicates
or invalid sequences of dates were identified, and only 0.8% of
patients were excluded because the gender was unknown or they
were diagnosed at postmortem or registered only through a death
certificate or because no follow-up was available after diagnosis.
Relative survival and the proportion cured were estimated for
children diagnosed with all types of leukaemia combined and
separately for lymphoid leukaemia and ANLL. Relative survival is
the ratio of the survival observed in a group of cancer patients and
the survival that would have been expected if they had only been
subjected to the background mortality observed in the general
population. It was estimated using a maximum likelihood
approach for individual records (Este`ve et al, 1994) using the
STATA algorithm strel (Coleman et al, 1999). Expected survival
was estimated by applying the background mortality rates in the
general population by age, sex and time period to the patient
population. Background mortality rates by sex and single year of
age at death up to age 99 were derived from life tables constructed
by the Government Actuary’s Department for Great Britain from
1980 onwards.
The relative survival function tends to reach a plateau at some
point after diagnosis; this plateau represents the proportion of
survivors for whom, as a group, there is no longer any excess
mortality compared with the general population. The value of the
function at the time point when this plateau is reached can be
taken as an estimate of the proportion of patients who are cured of
their disease (Figure 1). This approach can be used to derive a
further indicator, the average duration of time since diagnosis at
which cure can reasonably be declared (see Appendix for
equations). The percentage of children cured of leukaemia, by
period of diagnosis, was modelled from relative survival estimates
up to 20 years after diagnosis. As this approach refers to a
population, some long-term survivors will still die from their
cancer, and some patients who die before the time point at which
cure is declared (‘fatal’ cases) would have died from other causes.
The risk of death for ‘fatal’ cases was modelled as Weibull-
distributed with time since diagnosis (Verdecchia et al, 1998).
Average time to cure is estimated as the time at which an arbitrary
but small proportion of ‘fatal’ cases is still alive. In this study,
following a sensitivity analysis, average time to cure was defined as
the point at which 1% of ‘fatal’ cases were still alive (De Angelis
et al, 1999). The average time since diagnosis at which cure can
reasonably be declared is sensitive both to the sample size and to
the (arbitrary) percentage of ‘fatal’ cases still alive that is used to
determine the average time of cure. Formulae for the variance of
the average time to cure were developed to be able to assess the
variability of average time to cure in each analysis (see Appendix).
A nonlinear least squares method was used to fit the Weibull
model to the relative survival values by time since diagnosis. The
standard error was estimated using a standard linear approxima-
tion (Kendall and Stuart, 1969). Variance-weighted least squares
linear regression was used to evaluate time trends in survival, in
the percentage of children cured and in the average time to cure.
The period approach (Brenner and Gefeller, 1997) was used to
predict long-term relative survival (up to 20 years) for children
diagnosed during the 2-year period 1999–2000. This ‘predicted’
survival was then used to estimate the percentage of children
diagnosed during 1999–2000 who were expected to be cured, using
the Weibull model applied to follow-up data accrued during the
period 1999–2004.
RESULTS
Survival for children with leukaemia has improved significantly
since 1971 (Table 1). For all types of leukaemia combined, 5-year
survival increased from 33% for children diagnosed during 1971–
1975 to 79% for those diagnosed during 1996–2000. This
represents an estimated (linear) average increase of 1.9% every
year over the 25-year period between the midpoints of these
quinquennia.
Since 1971, survival for children with lymphoid leukaemia has
consistently been much higher than that for children diagnosed
with ANLL (Table 1). Five-year relative survival was 83% for
children diagnosed during 1996–2000 with lymphoid leukaemia
and 66% for those with ANLL. The average annual improvement in
survival over the entire period was higher for ANLL (2.4%) than
for lymphoid leukaemia (1.7%), although survival for ANLL
started from a much lower value.
Taking all types of leukaemia combined as a group, the
percentage of children who appear to have been cured has
increased significantly, from 25% for children diagnosed during
1971– 1975 to 68% for children diagnosed during 1991–1995
(Table 1), and it is predicted to increase to 73% for those most
recently diagnosed. Average time to cure increased from 11.0 years
(95% confidence interval (CI): 10–12) in children diagnosed
during 1971–1975 to 15.9 years (95% CI: 12–21) in children
diagnosed during 1986–1990 (average annual increase of 0.2 years;
Po0.001). In contrast to the steady improvement in the percentage
cured, the average time at which cure was declared increased most
rapidly during the 1980s.
The percentage of children cured is predicted to increase to 75%
for lymphoid leukaemia and 59% for ANLL (Figure 2). The average
duration of time since diagnosis at which cure can reasonably be
declared has increased from 12 years (95% CI: 11– 14) to 19 years
(95% CI: 14–26) for lymphoid leukaemia (average annual increase
of 0.3 years; Po0.001), but remained at about 5 years for ANLL
(Figure 3).
DISCUSSION
Survival and the proportion cured of childhood leukaemia have
both increased dramatically since the 1970s. But children with
lymphoid leukaemia, as a group, now experience excess mortality
for at least 19 years after diagnosis. Given this evidence of a
prolonged period of excess mortality, estimates of cure remain
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Figure 1 The schematic representation of the proportion of patients
who are ‘cured’ (shaded area) and the average time since diagnosis at
which cure can be declared (Tc).
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relevant today for lymphoid leukaemia survivors who were
diagnosed many years ago.
The robustness of estimates of cure for children diagnosed in
more recent years is dependent on the length of time before the
plateau of relative survival occurs and whether sufficient follow-up
time has been observed for the plateau to be detected. Estimates of
cure become less precise as the duration of available follow-up data
becomes shorter, although each child was followed for at least 9
years. When excess mortality continues beyond the most recent
time point for which follow-up data are available, the percentage
cured is derived by extrapolation of the cure model. This was done
for children diagnosed with lymphoid leukaemia during 1991–1995.
The prediction of cure for lymphoid leukaemia has much
narrower CIs than the estimate of cure for children diagnosed
during 1991–1995, because follow-up data for children diagnosed
during the 22 years 1979– 2000 contributed to the period analysis,
whereas only 13 years of follow-up were available for children
diagnosed during 1991– 1995. Period analysis provides the most
robust approach to predicting outcome for children diagnosed
most recently, but it is still only of limited value where new
treatment regimens have been introduced. The impact of these new
treatment regimens cannot yet be incorporated into long-term
survival predictions, because follow-up data are insufficient.
Remarkable improvements have been made in treating and
‘curing’ leukaemia since 1971. The evidence for risk-directed
therapy underpinning these huge gains in survival from childhood
Table 1 Survival and ‘cure’ trends for childhood leukaemia: Great Britain, children diagnosed during 1971–2000
Calendar period of diagnosis
1971–1975 1976–1980 1981–1985 1986–1990 1991–95 1996–2000
Average annual
changea
All types 95% CI 95% CI 95% CI 95% CI 95% CI 95% CI 95% CI
Number of patients 2379 2136 1942 2080 2215 2317
Five-year relative
survival (%)
32.8 30.9 34.7 46.0 43.8 48.1 61.2 59.0 63.3 68.6 66.5 70.5 76.1 74.3 77.8 79.0 77.2 80.7 1.9 1.8 1.9
Percentage ‘cured’ 24.7 23.8 25.7 38.7 38.1 39.4 54.1 53.1 55.0 61.4 59.5 63.4 67.5 64.9 70.1 NA NA NA 2.5 2.5 2.5
Average time to
‘cure’ (years)
11.0 9.9 12.3 11.2 10.2 12.2 12.8 11.2 14.7 15.9 12.2 20.7 FU FU FU NA NA NA 0.2 0.2 0.3
Lymphoid
Number of patients 1827 1726 1573 1675 1822 1873
Five-year relative
survival (%)
40.6 38.3 42.8 53.3 50.9 55.6 69.4 67.1 71.6 74.7 72.5 76.7 81.3 79.4 83.0 82.6 80.8 84.3 1.7 1.6 1.7
Percentage ‘cured’ 31.1 30.0 32.3 45.1 44.4 45.8 59.2 56.2 62.2 64.6 58.2 71.1 67.6 56.3 79.0 NA NA NA 2.6 2.6 2.6
Average time to
‘cure’ (years)
12.1 10.9 13.5 12.2 11.1 13.3 18.8 13.8 25.6 FU FU FU FU FU FU NA NA NA 0.3 0.3 0.3
ANLL
Number of patients 425 338 298 321 329 349
Five-year relative
survival (%)
5.5 3.7 8.0 14.3 10.8 18.2 26.3 21.5 31.4 44.6 39.1 50.0 51.9 46.4 57.2 65.8 60.4 70.6 2.4 2.2 2.6
Percentage ‘cured’ 4.7 4.3 5.2 12.8 11.9 13.6 25.1 24.5 25.7 42.8 41.9 43.6 51.3 50.4 52.3 NA NA NA 2.4 2.4 2.4
Average time to
‘cure’ (years)
4.5 4.1 4.9 5.0 4.4 5.7 4.3 3.9 4.8 4.5 3.9 5.3 4.7 4.1 5.3 NA NA NA 0.0 0.0 0.0
ANLL¼ acute nonlymphoblastic leukaemia; CI¼ confidence interval. FU – follow-up data were inadequate for estimating time to ‘cure’; NA – not available: estimates of ‘cure’
were not produced for the 1996–2000 period of diagnosis because the available follow-up was too short. aAverage annual increase over 25 years (1971–2004) for survival and
over 20 years (1971–1995) for ‘cure’. The estimate of trend was based on the midpoint of each of the intervals.
0
20
40
60
80
100
1971–75 1976–80 1981–85 1986–90 1991–95 Prediction
Calendar period of diagnosis
Pe
rc
en
ta
ge
 'c
ur
ed
'
Lymphoid leukaemia
Acute non-lymphoblastic
leukaemia
Figure 2 Trends in the percentage of children ‘cured’ of lymphoid
leukaemia and acute nonlymphoblastic leukaemia: Great Britain, children
diagnosed during 1971–1995. The predictions of the proportion cured
were made for children diagnosed during 1999–2000 and are based on
follow-up accrued during 1999–2004.
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Figure 3 Trends in the average time to ‘cure’ for children with lymphoid
leukaemia and acute nonlymphoblastic leukaemia by period of diagnosis:
Great Britain, children diagnosed during 1971–1995.
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leukaemia derives from an almost continuous series of national
trials that began in 1970, funded by the Medical Research Council
(MRC) (MRC Working Party on Leukaemia in Childhood, 1986;
Eden et al, 2000; Gibson et al, 2005). All the studies that have
examined long-term survival in childhood cancer patients, in
Britain and in other countries, have concluded that survivors
experienced excess mortality beyond 5 years after diagnosis, with a
10.8-fold excess in all-cause mortality in the United States and
Nordic countries (Hawkins, 1989; Robertson et al, 1994; Mertens
et al, 2001; Mo¨ller et al, 2001; Cardous-Ubbink et al, 2004).
These results may appear paradoxical, in that survival and the
proportion of children cured have both increased and excess
mortality has fallen, but excess mortality now lasts on average 7
years longer than it used to. Likely reasons for the increased
duration of excess mortality include an increase in the occurrence
of late relapse and of second cancers, as well as increased toxicity
of treatment and prolonged survival of ‘fatal’ cases (Vora et al,
1998; Robison and Bhatia, 2003; Pui et al, 2005). In the Nordic
countries, 300 deaths were seen in 5-year survivors of childhood
leukaemia; 85% of these were due to the primary leukaemia, 11%
due to the treatment for the first cancer and 3% died from a second
primary cancer (Mo¨ller et al, 2001).
Modern therapy has increased event-free survival, but late relapse
still occurs (Vora et al, 1998; Lawson et al, 2000; Roy et al, 2005;
Feltbower et al, 2007), although it can be unclear whether this is a
‘true’ relapse of the original leukaemia or the occurrence of a second
similar malignancy. It has been postulated, for example, that a
persistent preleukaemic clone may survive chemotherapy for the
original disease and later lead to a second, similar leukaemia, after
further events induce disease progression (Vora et al, 1998).
Radiotherapy and chemotherapy are associated with serious
complications, including cardiotoxicity, endocrinological effects,
neurocognitive and neuropsychological effects and second malig-
nancies (Neglia et al, 1991; Hawkins et al, 1996; Pui et al, 2003;
Robison and Bhatia, 2003; Jenkinson et al, 2004; Oeffinger et al,
2006). The risk of a second cancer has been found to be highest in
children who received irradiation therapy or suffered a relapse,
and this risk persists for up to 30 years after treatment (Kimball
Dalton et al, 1998; Lonig et al, 2000; Bhatia et al, 2002).
It remains to be seen whether the abandonment of cranial
irradiation therapy from the late 1990s (Hill et al, 2004) will lead to
a reduction in the occurrence of central nervous system tumours
in leukaemia survivors, and whether the reduction in total dose of
therapeutic agents, such as anthracylines, will reduce the
occurrence of cardiovascular complications.
The average length of time to cure is markedly shorter for ANLL
than for lymphoid leukaemia. A likely reason is that most relapses
occur early in ANLL and the overall survival is lower than that for
lymphoid leukaemia: survival beyond 5 years is thus virtually
equivalent to actual cure. As there are far fewer long-term
survivors for ANLL than for lymphoid leukaemia, we are not yet
in a position to assess long-term treatment-related toxicity in
ANLL beyond 5 years after diagnosis.
Excess morbidity and mortality in survivors of childhood
lymphoid leukaemia emphasise the need for long-term medical
surveillance of these children. Trends in the percentage of children
who can be considered cured of their leukaemia and the average
time since diagnosis at which cure can reasonably be declared
provide an additional approach to evaluating the long-term
outcome of leukaemia. These measures usefully supplement
estimates of 5-year survival, the traditional measure of prognosis.
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Appendix
In the Weibull mixture survival model used to estimate ‘cure’, the
cumulative relative survival (S) is given by:
SðtÞ ¼ P þ ðQÞ expððltÞbÞ
where P represents the proportion of patients ‘cured’, Q represents
the proportion of ‘fatal’ cases, l is the excess hazard, t is the time
since diagnosis and b is the ‘shape’ parameter, indicating change in
the excess hazard with time since diagnosis (Verdecchia et al,
1998). The Weibull distribution includes b, so if b is less than 1, the
excess hazard (l) is decreasing with time, and if b is greater than 1,
the excess hazard is increasing.
The proportion of ‘cured’ cases (P) is estimated from the
intercept of this model. The function (Q)exp(lt)b models relative
survival until a plateau occurs.
Average time to ‘cure’ (Tc) provides the time at which only a
proportion, a, of ‘fatal’ cases are still alive. In this work, a was
taken to be 1%, following an evaluation of the estimate of average
time to ‘cure’ to the proportion of ‘fatal’ cases remaining alive. De
Angelis et al (1999) define average time to ‘cure’ as:
Tc ¼  lnða1=bÞ=l
A standard Taylor series approximation was used to obtain the
variance of average time to ‘cure’ (Kendall and Stuart, 1969). The
formulae, which were programmed in STATA, are given below:
A ¼ VarðlÞ  1
l
 2
B ¼ VarðbÞ  1
b4
log  log a
1  P
  h i2
C ¼ VarðPÞ  1
b2
a=ð1  PÞ
 logða=ð1  PÞÞ
 	2
D ¼ 2covðlbÞ  1
lb2
log  log að1  PÞ
  
E ¼ 2covðlPÞ  1
lb
a=ð1  PÞ
 logða=ð1  PÞÞ
 	
F ¼ 2covðbPÞ  1
b3
 log að1  PÞ
 	
a=ð1  PÞ
 logða=ð1  PÞÞ
 	
where Var is the variance of each parameter and cov is the
covariance of the stated parameters. Then the variance of average
time to ‘cure’ is given by:
VarðTcÞ ¼ A þ B þ C þ D  E  F
and the 95% confidence interval around average time to ‘cure’ is
given by a standard Normal approximation:
95%CI ¼ expðlogðTcÞ  1:96
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
VarðTcÞ
p
Þ
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